[Osteoclast-activating factors (OAF)].

作者信息

Sato Kanji

机构信息

Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University.

出版信息

Nihon Rinsho. 2004 Dec;62 Suppl 12:228-31.

PMID:15658306

Abstract

摘要

相似文献

[Osteoclast-activating factors (OAF)].

Nihon Rinsho. 2004 Dec;62 Suppl 12:228-31.

Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).

Br J Haematol. 2004 Sep;126(5):686-9. doi: 10.1111/j.1365-2141.2004.05092.x.

[Molecular mechanism of bone metabolism].

Nihon Naika Gakkai Zasshi. 2000 Oct 10;89(10):2046-53.

Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.

Clin Endocrinol (Oxf). 2005 Jan;62(1):92-8. doi: 10.1111/j.1365-2265.2004.02179.x.

Evidence of a role for RANKL in the development of myeloma bone disease.

Curr Opin Pharmacol. 2004 Aug;4(4):340-6. doi: 10.1016/j.coph.2004.03.011.

Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.

Medscape Womens Health. 2000 Mar;5(2):5.

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

Exp Hematol. 2004 Aug;32(8):685-91. doi: 10.1016/j.exphem.2004.03.015.

Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?

J Endocrinol Invest. 2005;28(10 Suppl):14-22.

[Recent advance in basic research for osteoporosis].

Nihon Rinsho. 2004 Feb;62 Suppl 2:13-20.

Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?

J Rheumatol. 2004 May;31(5):986-91.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验